Why Assigning Patents To Native American Tribes To Avoid Inter Partes Review Is Bad Medicine
Here are three big reasons why, according to IP columnist Tom Kulik.
Here are three big reasons why, according to IP columnist Tom Kulik.
Columnist Gaston Kroub interviews Manny Schecter, a leading voice in the IP community.
Leveraging agentic AI to triage, prioritize, and automate the law department inbox.
If this tactic is allowed, it will be a big win for Big Pharma -- and a big loss for patients and consumers.
The Supreme Court just agreed to decide a profoundly important question in patent law right now.